atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
pharma · Metastatic Lung Non-Small Cell Carcinoma · COVID-19 · OTLC
Oncotelic Therapeutics
Oncotelic Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Seoul, KR HQ
2020 Founded
14 Employees
Public company Type
OTLC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seoul, KR
- Founded
- 2020
- Employees
- 14
- Programs
- 4
- Drugs
- 3
- Patents
- 1
Oncotelic Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Oncotelic Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Oncotelic Therapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
Development asset linked to Oncotelic Therapeutics in public FDA and regional records.